SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.88-0.4%3:25 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (5196)12/20/2001 8:22:53 PM
From: Biomaven  Read Replies (2) of 52153
 
Thanks, Harry.

At least the money doesn't flow right back to CEPH as revenue, which is what ELN and others managed. (The JV intermediary would hire the parent to perform the research, and so part of the cash did a U-turn and came back as revenue). I thus don't view this as similar to ELN's practices.

Given the tyranny of earnings straitjacket you refer to, I think this is a smart deal. The key thing about building a market is its cumulative nature - spending the bucks now provides a revenue stream annuity that lasts until the patent expires.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News